Medical Developments International (FRA:M5D) EBIT: €-0.18 Mil (TTM As of Dec. 2025)


FRA:M5D Medical Developments International Ltd FRA:M5D
32 GF Score
Price €0.20
GF Value €0.35
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medical Developments International EBIT?

Medical Developments International FRA:M5D +1.55% 32 EBIT is €-0.18 Mil as of Dec. 2025. GuruFocus rates FRA:M5D with a GF Score™ of 32/100 and a GF Value™ of €0.35 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Medical Developments International's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €-0.11 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.18 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Medical Developments International's annualized ROC % for the quarter that ended in Dec. 2025 was -0.16%. Medical Developments International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -2.01%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Medical Developments International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1.00%.

Medical Developments International  (FRA:M5D) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Medical Developments International's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-0.04 * ( 1 - 1.54% )/( (23.743 + 24.047)/ 2 )
=-0.039384/23.895
=-0.16 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=37.477 - 3.666 - ( 10.068 - max(0, 4.416 - 20.061+10.068))
=23.743

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=36.071 - 2.447 - ( 9.577 - max(0, 3.155 - 19.153+9.577))
=24.047

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Medical Developments International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.222/( ( (5.045 + max(5.691, 0)) + (4.742 + max(6.608, 0)) )/ 2 )
=-0.222/( ( 10.736 + 11.35 )/ 2 )
=-0.222/11.043
=-2.01 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.253 + 5.334 + 0.34) - (3.666 + 0.183 + 0.387)
=5.691

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.756 + 4.82 + 0) - (2.447 + 0.033 + 0.488)
=6.608

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Medical Developments International's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-0.175/17.547
=-1.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medical Developments International EBIT Related Terms

Medical Developments International EBIT Historical Data

* Premium members only.

The historical data trend for Medical Developments International's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medical Developments International EBIT Chart

Medical Developments International Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.50 -10.51 -4.58 -20.26 0.14

Medical Developments International Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.82 -12.40 0.22 -0.06 -0.11

FRA:M5D vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medical Developments International EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medical Developments International's EV-to-EBIT falls into.


FRA:M5D
32GF Score
Medical Developments International Ltd FRA:M5D
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medical Developments International EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-0.18 Mil mean?
Medical Developments International (FRA:M5D) has a EBIT of €-0.18 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medical Developments International.
Is Medical Developments International's EBIT too high?
Medical Developments International's current EBIT is €-0.18 Mil. Overall, Medical Developments International has a GF Score™ of 32/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's EBIT compare to ZTS?
Medical Developments International's EBIT of €-0.18 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Medical Developments International. Medical Developments International's current EBIT is €-0.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (FRA:M5D) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.35, compared to a current price of €0.20 — trading 43.7% below its estimated fair value. The current EBIT is €-0.18 Mil. Medical Developments International's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Medical Developments International (FRA:M5D), the current EBIT is €-0.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medical Developments International (FRA:M5D) Overvalued in 2026?

Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued. The current stock price of €0.20 is trading 43.7% below its estimated GF Value™ of €0.35. GuruFocus considers Medical Developments International to be Significantly Undervalued.

Key valuation signals for FRA:M5D:

  • EBIT: €-0.18 Mil
  • GF Value™: €0.35 vs. price of €0.20 (43.7% below fair value)
  • GF Score™: 32/100 with 2 warning signs

No single metric tells the full story. See the FRA:M5D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medical Developments International Business Description

Other Exchanges MDDVF:USAMVP:Australia
Address 4 Caribbean Drive, Scoresby, VIC, AUS, 3179
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
32GF Score

Get the complete analysis for FRA:M5D

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€0.35
GF Value